BioAge Labs has given up on its lead obesity candidate. Weeks after stopping a trial in response to phase 2 data, the biotech has jettisoned the molecule and shifted its focus to a preclinical ...

It’s been a rocky few months for BioAge Labs, which shuttered a Phase II trial of its lead candidate azelaprag Tuesday after ...

For patients with chronic viral hepatitis, clinicians instinctively rely on liver enzyme measurements to estimate disease activity and assess need for liver biopsy or antiviral treatment.

The findings align with current guidelines recommending liver enzyme monitoring in the medical follow-up of patients with celiac disease. "In addition to being vigilant to signs of progressive ...

University of Illinois Chicago scientists have redesigned a treatment for the most common pediatric leukemia to eliminate its severe side effects, like blood clots and liver damage. If approved, the ...